Is MXE legal in South Africa?

Legal status

Controlled as a Schedule 7 substance under the Medicines and Related Substances Act 101 of 1965, as at the SAHPRA consolidation of 1 August 2025; it is not printed in the Drugs and Drug Trafficking Act 140 of 1992.

Consequences if caught

Schedule 7 prints it on page 196 as "Methoxetamine (MXE).", and separately prints "3-Methoxyphencyclidine." and phencyclidine with its named congeners. Section 22A (9) (a) (i) of the Medicines Act says no person shall "acquire, use, possess, manufacture or supply any Schedule 7 or Schedule 8 substance" unless the Director-General has issued a permit for it, and its proviso lets the Director-General authorise use only to provide a medical practitioner, analyst, researcher or veterinarian with the substance for a particular patient or for education, analysis or research. Section 29 (k) makes it an offence to contravene "any provision of section 22A", and section 30 (1) makes a person convicted of an offence referred to in section 29 "liable to a fine, or to imprisonment for a period not exceeding 10 years." Section 30 (2) lets the court declare the substance forfeited to the State, and section 30 (4) makes a magistrate's court competent to impose the penalty. Section 22A (11) (a) also forbids importing or exporting any Schedule 7 substance without a permit, and (11) (b) says such a permit "may be issued for any purpose other than the satisfaction or relief of a habit or craving". Under the Drugs Act the position is different. Part III prints "Phencyclidine and the congeners thereof, namely, N-ethyl-1-phenylcyclohexylamine (PCE), 1-(1-phenylcyclohexyl) pyrrolidine (PHP or PCPY) and 1-[1-(2-thienyl) cyclohexyl] piperidine (TCP)." naming three congeners and no class, and this substance is not among them. The substance it is most often compared with, ketamine, is itself unlisted, so the chain from the printed entry to this molecule runs through a compound the schedule never mentions. A homologue limb applied through an unlisted intermediate is a longer reach than one applied directly, and the Act says nothing about how far it goes. The Drugs Act limb that could still reach it is Part III paragraph 2 (e), "(e) all homologues of the listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance or exhibit pharmacodynamic properties similar to the listed substances in this Part of the Schedule), unless listed separately in any Part of Schedule 2." The equivalent limb in Part I is paragraph 2 (c). If it does reach the substance, use or possession falls under section 4 (b), an offence under section 13 (d) punishable under section 17 (d) by such fine as the court may deem fit, imprisonment for a period not exceeding 15 years, or both, and dealing falls under section 5 (b), an offence under section 13 (f) punishable under section 17 (e) by imprisonment for a period not exceeding 25 years, or that imprisonment and a fine. If it does not, the Drugs Act does not reach the substance at all. The Act supplies no test for deciding a homologue case. Capital exposure: none, and life exposure: none. Section 30 (1) of the Medicines Act fixes the penalty for an offence under section 29 at a fine or imprisonment for a period not exceeding 10 years, and section 17 sets out the whole penalty scale of the Drugs Act, whose highest figure is 25 years for dealing; neither Act carries a death sentence or a sentence of life imprisonment.

If prescribed or medical

There is no prescription route. Section 22A (9) (a) (i) says no person shall "acquire, use, possess, manufacture or supply any Schedule 7 or Schedule 8 substance" unless the Director-General has issued a permit for it, and its proviso lets the Director-General authorise use only to provide a medical practitioner, analyst, researcher or veterinarian with the substance for a particular patient or for education, analysis or research. The Drugs Act's own exceptions in section 4, paragraphs (i) to (vi), run through a practitioner acting in accordance with the Medicines Act, and section 2 of the Drugs Act says it applies "in addition to, and not in substitution for" the Medicines Act.

Documentation

Medicines Act search record, 3 October 2026. Terms searched: methoxetamine, MXE and phencyclidine. Methoxetamine returns one Schedule 7 entry; ketamine, the compound it is usually compared with, is in Schedule 5. The consolidation is a text PDF of 199 pages and was searched as extracted text, every schedule from 0 to 8. The Medicines Act schedules are stated as at the SAHPRA Consolidated Schedules of 1 August 2025, which on a comparison of two of its changes, the inserted fluconazole entry in Schedule 2 and the reworded nicotine metered spray line, both read on pages 4 and 6 of the scanned notice, already carry Government Notice R6466 of 1 August 2025; the rest of that notice was not read. That consolidation is read with Government Notice 7446 in Government Gazette 54627 of 8 May 2026, whose only change is to insert a veterinary yohimbine entry in Schedule 4; both were read on 3 October 2026. SAHPRA now labels the 1 August 2025 file an archived version and offers its July 2026 consolidation only through a Microsoft sign in that refused an anonymous request, so that file was not read, and this does not rule out a later amendment. The text of the Medicines Act read is the consolidation published in Government Gazette 40869 of 26 May 2017, whose list of amending Acts ends at Act 14 of 2015; a search on 3 October 2026 found no later amending Act, which does not rule one out. Drugs Act search record carried from the earlier cell. Search record. The terms searched were mxe, methoxetamine, methoxyketamine, arylcyclohexylamine and eticyclidine. The last of these is the one that returns something, because the printed congener list names the N-ethyl phenylcyclohexylamine, and that is the closest the schedule comes to this chemistry. The text read for this cell is the Juta consolidation of the Act downloaded on 29 May 2025, taken from the Department of Justice copy at justice.gov.za whose sha256 begins bc1216a3. It carries the substitution of Schedules 1 and 2 by section 2 of Act 14 of 2022 with effect from 14 December 2022, and it marks section 7 of the Cannabis for Private Purposes Act 7 of 2024, the provision that would amend Schedule 2 again, as not yet put into operation by proclamation. The schedules are stated as at that consolidation and this does not rule out a later amendment made or commenced since.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with South Africa’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.